LLT1 过表达导致同种异体 NK 抵抗并促进增强型通用 CAR-T 细胞的生成

LLT1 overexpression renders allogeneic-NK resistance and facilitates the generation of enhanced universal CAR-T cells.

根据这些结果，LLT1 过表达增强了 UCAR-T 细胞的活性并防止同种异体排斥反应，为通用型 CAR-T 细胞疗法的开发提供了重要见解。

用 CD38 CAR 工程化 NK 细胞克服急性髓系白血病中 CD226 相关免疫逃逸

Overcoming CD226-related immune evasion in acute myeloid leukemia with CD38 CAR-engineered NK cells.

CD38-CAR 人 NK 细胞联合 ATRA 增强对表达 CD38 的血液系统恶性肿瘤的细胞毒性

CD38-CAR human NK cells in combination with ATRA enhance cytotoxicity against CD38-expressing hematologic malignancies.

CD38 特异性 CAR 整合到 CD38 基因座并由不同启动子驱动，导致 T 细胞和 NK 细胞具有不同的抗肿瘤活性

CD38-Specific CAR Integrated into CD38 Locus Driven by Different Promoters Causes Distinct Antitumor Activities of T and NK Cells.

表达亲和力优化 CD38 嵌合抗原受体的 CD38 敲除 NK 细胞成功靶向急性髓系白血病并减少效应细胞自相残杀

CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with red

进入基因编辑 NK 细胞治疗策略的多元宇宙

Into the multiverse of gene edited NK cell-based therapeutic strategies.